Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu; Masahiro Tsuboi; Jie He; Thomas John; Christian Grohé; Margarita Majem; Jonathan W. Goldman; К. К. Лактионов; Sang‐We Kim; Terufumi Kato; Huu-Vinh Vu; Shun Lü; Kye Young Lee; Charuwan Akewanlop; Chong‐Jen Yu; Filippo de Marinis; Laura Bonanno; Manuel Dómine; Frances A. Shepherd; Lingmin Zeng; Rachel Hodge; Ajlan Atasoy; Yuri Rukazenkov; Roy S. Herbst

doi:10.1056/nejmoa2027071

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2020) studied this question.

synapsesocial.com/papers/69d1ba57c1780f2df99203b7 https://doi.org/10.1056/nejmoa2027071

View Full Paper

Ask AI

Bookmark

Share

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading